Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.
Phase 2a SLS009 Trial in R/R AML Completes Enrollment and Shows Efficacy
Phase 2a data show no dose-limiting toxicities with SLS009 among patients with relapsed/refractory acute myeloid leukemia.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Uproleselan Combo Improves Survival Vs Chemo in Relapsed/Refractory AML
Toxicity in this phase 3 trial was comparable with prior reports of chemotherapy among patients with relapsed/refractory acute myeloid leukemia.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
VEN-HMA May Prolong Survival in Elderly Acute Myeloid Leukemia Population
A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.
Pre-Transplant FLT3-ITD Detection Confers Relapse/Death Risk in AML
Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.